Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM Bio

Cell line to be used to support research and development of biotherapeutics across therapeutic areas Cambridge, UK: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase [...]

Micromeritics Delivers Optimized Solution for Carbon Black Testing in accordance with latest ASTM Classification

Introducing the Dynamic Void Volume Analyzer (DVVA) II for automated, environmentally benign testing, for rubber compounding  Norcross, GA, USA — Micromeritics Instrument Corp., a leader in material characterization technology, has developed an optimized, automated solution for customers looking to characterize carbon blacks in accordance with the newly revised ASTM D1765-18 Classification System for Carbon Blacks [...]

Companies Join Forces to Address Urgently Needed Quality Control of CRISPR Genome-editingSAN DIEGO, Jan. 21, 2020 /PRNewswire-PRWeb/ — COBO Technologies and Cardea Bio partner to bring solutions to challenges with the precision of Genome editing. The partners have agreed to co-develop and market a portfolio of CRISPR QC products and services for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the parties aim to develop a COBO branded QC device based on Cardea’s CRISPR-Chip™ QC technology for use before and after genome-editing in the pre-clinical setting. With the new strategic partnership, the Danish company COBO Technologies, which specializes in quality control of CRISPR-modified cells of any kind, will collaborate with San Diego-based (bio)technology infrastructure company Cardea to bring powerful QC products and services for better genome-editing applications to the global life science and agriculture markets. The partners have begun product development of a CRISPR QC tool based on Cardea’s innovative biology-gated transistors™. By adding CRISPR-Chip QC capabilities to the Cardean transistor infrastructure, the teams will be able to achieve sensitive and fast quality control of CRISPR experiment subparts (e.g. gRNAs, Cas systems and versions, on-and-off target activity) -and the resulting genome modified cells. “There is a rapidly increasing need for better quality control of genome-edited cells. With this new QC tool based on CRISPR-Chip, researchers can easily confirm the precision of their CRISPR experiments, for example, detection of potential off-target events,” says Jens-Ole Bock, CEO and founder of COBO Technologies. COBO’s tools include the proprietary CRISPR InDel Profiling Platform (CIPP™) developed for in-depth detection of genome editing outcomes and PIPPR® created for extensive proteome expression profiling after CRISPR edits. Beginning in 2020, the strong sales team at Nanosens (a wholly-owned Cardea subsidiary) will market and sell COBO’s services and products for quality control in the US.

SAN DIEGO — COBO Technologies and Cardea Bio partner to bring solutions to challenges with the precision of Genome editing. The partners have agreed to co-develop and market a portfolio of CRISPR QC products and services for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the parties aim to develop a [...]

Genomenon’s Mastermind Continues to Outpace Qiagen’s HGMD Genetic Database

ANN ARBOR, Mich. — Genomenon® announced that over 175,000 recently documented genetic variants (DNA mutations) have been added to the Mastermind® Genomic Search Engine in the 4th quarter of 2019, for a cumulative total of more than 5.9 million genetic variants. This number reflects the rapidly accelerating pace of genomic discovery, and stands in stark contrast [...]

CellFE Raises $3.6M in Seed Round Co-led by Cota Capital and Dynamk Capital

SAN CARLOS, Calif., Jan. 16, 2020 — CellFE, Inc., an innovative startup developing a microfluidics based device to deliver gene-editing molecules, today announced it has raised $3.6 million in an initial Series Seed. The oversubscribed round is co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures. The round is expected to close with additional investors [...]

LUM trains the worldwide sales experts on the new particle measurement devices and looks optimistically into the future

( Berlin,16/1/20)  From January 27th to 29th the International Sales Meeting will take place at the headquarters of LUM GmbH in Berlin-Adlershof for the 21st time in a row. The sales experts of the LUM companies from Asia, Europe and North America exchange technical information with external sales partners from all over the world. This is where [...]

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

SANTA CLARA, Calif.– Agilent Technologies Inc. (NYSE: A) is collaborating with researchers at two UK universities who are looking into the risk factors for atopic eczema (also known as atopic dermatitis), a chronic skin condition that affects one in five children and one in 12 adults. The aim of the collaboration is to help the medical [...]

Discover 18 Wells for Cost-Effective Cell Culture and High-Resolution Microscopy

Munich, Germany – Perform high-resolution, cost-effective cell culture experiments with ibidi’s latest innovative labware technology, the µ-Slide 18 Well family. With its thin ibidi Polymer Coverslip Bottom, the µ-Slide 18 Well allows for excellent cell adhesion onto the tissue culture-treated surface. In addition, it has the highest optical quality and is ideally suited for a variety of [...]

Twist Bioscience Selected as DNA Synthesis Provider for DNA Data Storage Project Under Intelligence Advanced Research Projects Activity (IARPA) Molecular Information Storage (MIST) Program

— Contract Focused on Making DNA Data Storage Commercially Accessible — SAN FRANCISCO– Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has been selected as a subcontractor to Georgia Tech Research Institute (GTRI) to undertake the DNA [...]

Twist Bioscience Announces Strategic Collaboration With Schrödinger for Drug Discovery

SOUTH SAN FRANCISCO, Calif.–Jan. 15, 2020– Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced today a collaboration with Schrödinger, Inc., a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies’ [...]

Access IBO on Knowledge Center
Register for Free Trial Login for Access

Register for Free Trial Login for Access

Lost your password? Register